MilliporeSigma
  • Home
  • Search Results
  • Time to 12-month remission and treatment failure for generalised and unclassified epilepsy.

Time to 12-month remission and treatment failure for generalised and unclassified epilepsy.

Journal of neurology, neurosurgery, and psychiatry (2013-12-03)
Laura J Bonnett, Catrin Tudur Smith, David Smith, Paula R Williamson, David Chadwick, Anthony G Marson
ABSTRACT

To develop prognostic models for time to 12-month remission and time to treatment failure after initiating antiepileptic drug monotherapy for generalised and unclassified epilepsy. We analysed data from the Standard and New Antiepileptic Drug (arm B) study, a randomised trial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or unclassified epilepsy. Multivariable regression modelling was used to investigate how clinical factors affect the probability of achieving 12-month remission and treatment failure. Significant factors in the multivariable model for time to 12-month remission were having a relative with epilepsy, neurological insult, total number of tonic-clonic seizures before randomisation, seizure type and treatment. Significant factors in the multivariable model for time to treatment failure were treatment history (antiepileptic drug treatment prior to randomisation), EEG result, seizure type and treatment. The models described within this paper can be used to identify patients most likely to achieve 12-month remission and most likely to have treatment failure, aiding individual patient risk stratification and the design and analysis of future epilepsy trials.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Propylpentanoic acid
Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Valproic acid, United States Pharmacopeia (USP) Reference Standard
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Valproic acid, European Pharmacopoeia (EP) Reference Standard
Supelco
Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Lamotrigine, ≥98%, powder
Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Lamotrigine, United States Pharmacopeia (USP) Reference Standard
Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard
Lamotrigine, European Pharmacopoeia (EP) Reference Standard
Supelco
Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Topiramate, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Topiramate, ≥98% (HPLC), solid